Hydrogel, porous titanium / hydrogel composite implant material and preparation method thereof
By introducing acrylic β-cyclodextrin, acrylic sodium alendronate, and gelatin hydrogel into porous titanium alloys, a porous titanium/hydrogel composite material is formed, which solves the problem of insufficient bioinertness of traditional porous titanium alloys in segmental bone defect repair and realizes rapid growth and effective integration of bone tissue.
Patent Information
- Application Number
- CN202511360607.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-23
- Publication Date
- 2026-01-16
AI Technical Summary
When traditional porous titanium alloys are used to repair segmental bone defects, their bioinertness leads to insufficient osteoinduction activity, making it difficult to promote the directional differentiation of osteoblasts and the formation of new bone tissue. Furthermore, they lack nutrients and osteogenic sites, making it difficult to create a local microenvironment conducive to the growth of new bone tissue.
A porous titanium/hydrogel composite implant material is formed by using a hydrogel composed of acrylic β-cyclodextrin, acrylic sodium alendronate, gelatin and chemokines, which is photocrosslinked and cured to form a porous network structure. This is combined with porous titanium alloy material to recruit bone marrow mesenchymal stem cells and promote their osteogenic differentiation.
It significantly improved the growth capacity and osseointegration of new bone tissue, promoted the repair of segmental bone defects, and provided excellent osseointegration and osteogenic repair effects.
Smart Images

Figure CN121338098A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the technical field of biomedical materials, and particularly relates to a hydrogel, a porous titanium / hydrogel composite implant material and a preparation method thereof. BACKGROUND
[0002] Segmental bone defects (SBDs) generally refer to bone defects with a length exceeding 1.5 times of the diameter of a long bone or 1 / 5-1 / 4 of the total length, which are often caused by high-energy trauma, infection and tumor resection, etc., and cause load-bearing disorders, activity limitations and functional impairments of the corresponding limbs. Due to the large volume of bone defects and the disorder of local tissue microenvironment, the body is difficult to effectively repair itself after SBDs occur, and therefore it is urgent to develop an effective strategy for repairing SBDs.
[0003] In recent years, porous titanium alloy (pTi-alloy) materials are considered as one of the ideal candidate materials for repairing SBDs due to their excellent biocompatibility, superior mechanical strength, wear resistance and corrosion resistance, etc. However, in practical applications, the traditional porous titanium alloy still has some problems: (1) the biological inertia of the porous titanium alloy itself leads to insufficient osteoinductive activity, and it is difficult to effectively promote the directional differentiation of osteoblasts and the formation of new bone tissue; (2) the porous titanium alloy is in a biological inert state due to the lack of nutrients (such as the lack of calcium ions (Ca 2+ ), magnesium ions (Mg 2+ ) and the like) and osteogenic sites (such as Ca 2+ / Mg 2+ binding sites), and it is difficult to construct a local microenvironment conducive to the growth of new bone tissue. SUMMARY
[0004] The present application provides a hydrogel, which has a porous network structure, a high elastic modulus, a high fatigue resistance and excellent biocompatibility, and also has the ability to recruit bone marrow mesenchymal stem cells (BMSCs) and the ability to promote the osteogenic differentiation of BMSCs; the porous titanium / hydrogel composite implant material prepared by using the hydrogel can effectively promote the growth of new bone tissue, has excellent osteointegration ability, and the osteogenic repair effect and the osteointegration effect are obviously improved, thereby providing a new treatment approach for the repair treatment of segmental bone defects (SBDs) and having important medical significance.
[0005] The present application also provides a porous titanium / hydrogel composite implant material comprising the above hydrogel, which can effectively promote the growth of new bone tissue, has excellent osteointegration ability, and the osteogenic repair effect and the osteointegration effect are obviously improved.
[0006] The application further provides a preparation method of the porous titanium / hydrogel composite implant material, and the porous titanium / hydrogel composite implant material prepared by the method can effectively promote the growth of new bone tissue, has excellent bone integration capacity, and the osteogenesis repair effect and bone integration effect are obviously improved.
[0007] The first aspect of the application provides a hydrogel, which is obtained by photo-crosslinking solidification of a hydrogel precursor solution comprising acrylated beta-cyclodextrin, acrylated alendronate sodium, gelatin and a chemotactic factor;
[0008] The acrylated beta-cyclodextrin has a structural formula as shown in formula (1), and the acrylated alendronate sodium has a structural formula as shown in formula (2):
[0009]
[0010] The chemotactic factor is any one of SDF-1 alpha, CCL25, VEGF and stem cell homing peptide.
[0011] The hydrogel as described above, wherein the mass ratio of the acrylated beta-cyclodextrin, the acrylated alendronate sodium, the gelatin and the chemotactic factor in the hydrogel precursor solution is (4-6):(1.5-2.5):(3-5):2.5*10 -9 .
[0012] The hydrogel as described above, wherein the chemotactic factor is at least one of SDF-1 alpha, CCL25, VEGF and stem cell homing peptide.
[0013] The hydrogel as described above, wherein the photo-crosslinking solidification comprises: photo-crosslinking solidification under irradiation of 5-15 mW / cm 2 , 365 nm-405 nm violet light for 1 min-10 min.
[0014] The hydrogel as described above, wherein the acrylated beta-cyclodextrin is obtained by a preparation method comprising the following process:
[0015] Beta-cyclodextrin, dimethylformamide and triethylamine are mixed to obtain a beta-cyclodextrin solution, acryloyl chloride is added to the beta-cyclodextrin solution under ice bath conditions for stirring reaction, after the reaction is completed, insoluble substances are removed by filtration, rotary evaporation is performed, precipitation is performed in acetone, washing and drying are performed, and the acrylated beta-cyclodextrin is obtained.
[0016] The hydrogel as described above, wherein the acrylated alendronate sodium is obtained by a preparation method comprising the following process:
[0017] Sodium alendronate, potassium carbonate, ethyl ether and sodium hydroxide are dissolved in water to prepare a sodium alendronate solution, acryloyl chloride is dissolved in anhydrous ethyl ether to prepare an acryloyl chloride ethyl ether solution, the acryloyl chloride ethyl ether solution is added to the sodium alendronate solution under ice bath condition and stirred to react, after the reaction is completed, the solution is acidified to pH=1-3 with hydrochloric acid, extracted with ethyl ether, adjusted to pH=6.5-7.5, precipitated in ethanol, and freeze-dried to obtain the acrylated sodium alendronate.
[0018] The second aspect of the present application provides a porous titanium / hydrogel composite implant material, comprising a porous titanium alloy material and a hydrogel infused in the pores of the porous titanium alloy material.
[0019] The hydrogel is the hydrogel described above.
[0020] The porous titanium / hydrogel composite implant material described above, the mass of the hydrogel accounts for 75%-85% of the total mass of the porous titanium / hydrogel composite implant material.
[0021] The third aspect of the present application provides a preparation method of the porous titanium / hydrogel composite implant material, comprising the following steps:
[0022] (1) mixing acrylated β-cyclodextrin, acrylated sodium alendronate, gelatin, a chemokine and a solvent to prepare a hydrogel precursor solution;
[0023] (2) infusing the hydrogel precursor solution into the pores of a porous titanium alloy material, adding a phenyl(2,4,6-trimethylbenzoyl) lithium phosphate solution, and photo-crosslinking and curing to obtain a porous titanium / hydrogel composite implant material.
[0024] The preparation method of the porous titanium / hydrogel composite implant material described above, the concentration of the phenyl(2,4,6-trimethylbenzoyl) lithium phosphate solution is 5mg / mL-15mg / mL.
[0025] The scheme of the present application has at least the following effects:
[0026] The hydrogel provided by this invention is obtained by photocrosslinking and curing a hydrogel precursor solution comprising acrylic β-cyclodextrin (Ac-β-CD), acrylic alendronate sodium (Ac-ALN), gelatin, and chemokines. This hydrogel possesses a porous network structure, high elastic modulus, high fatigue resistance, and excellent biocompatibility. It also has the ability to recruit bone marrow mesenchymal stem cells (BMSCs) and promote their osteogenic differentiation. The porous titanium / hydrogel composite implant material prepared using this hydrogel can effectively promote the growth of new bone tissue, exhibits excellent osteointegration capacity, and significantly improves osteogenic repair and osteointegration effects. This provides a new treatment approach for the repair and treatment of segmental bone defects (SBDs) and has significant medical implications. Attached Figure Description
[0027] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0028] Figure 1 The 1H NMR spectra of β-cyclodextrin (β-CD) and acrylic β-cyclodextrin (Ac-β-CD) in Example 1 of this invention;
[0029] Figure 2 The 1H NMR spectra of sodium alendronate (ALN) and acrylated sodium alendronate (Ac-ALN) in Example 1 of this invention;
[0030] Figure 3 This is a scanning electron microscope image of the hydrogel in Example 1 of the present invention;
[0031] Figure 4 The X-ray energy dispersive spectroscopy (EDS) results of the hydrogel in Example 1 of this invention are shown below.
[0032] Figure 5 The mechanical property test results of the hydrogel in Example 1 of this invention are shown below. Figure 5 'a' represents the uniaxial compressive stress / strain curve of the hydrogel. Figure 5 b represents the stress relaxation curve of the hydrogel. Figure 5 c represents the cyclic compressive stress / strain curve of the hydrogel. Figure 5 d represents the rheological curve of the hydrogel;
[0033] Figure 6 The mechanical property test results of the hydrogel in Comparative Example 2 of this invention are shown below. Figure 6 In the figure, 'a' represents the uniaxial compressive stress / strain curve of the hydrogel in Comparative Example 2.Figure 6 b is the uniaxial compression stress / strain curve of the hydrogel in Example 1;
[0034] Figure 7 are the biocompatibility test results of the hydrogel in Example 1 of the present application;
[0035] Figure 8 are the cell recruitment ability test results of the hydrogel in Example 1 of the present application, wherein Figure 8 a is the image of BMSCs seeded on the surface of the hydrogel for 6h under confocal fluorescence microscope, and b is the image of BMSCs seeded on the surface of the hydrogel for 30h under confocal microscope;
[0036] Figure 9 are the staining results of the hydrogel experimental group (Hydrogel) and the control group (Control) in the cell osteogenic differentiation ability test (1) of the present application;
[0037] Figure 10 are the alkaline phosphatase activity test results of the control group (Ti), the Ti+Gel+Ac-Aln+SDF1a group (Ti+Gel+Ac-Aln+SDF1a), the Ti+Gel+SDF-1a group (Ti+Gel+SDF-1a) and the Ti+Gel+Ac-Aln group (Ti+Gel+Ac-Aln) in the cell osteogenic differentiation ability test (2) of the present application;
[0038] Figure 11 are the performance tests of the porous titanium / hydrogel composite implant material of the present application, wherein Figure 11 a is the femur of a New Zealand white rabbit, Figure 11 b and c are the real images of the 3D printed porous titanium alloy, Figure 11 d is a pressurized perfusion system designed using a 5ml syringe, Figure 11 e is an image of the hydrogel formed by the hydrogel precursor solution perfused in the pores of the porous titanium alloy material;
[0039] Figure 12 are the performance test results of the porous titanium / hydrogel composite implant material of the present application, Figure 12 a is the bone volume fraction calculated after Micro-CT detection of each group, Figure 12 b is the trabecular bone thickness of each group, Figure 12 c is the trabecular bone number of each group, Figure 12 d is the trabecular bone spacing of each group. DETAILED DESCRIPTION
[0040] In order to make the objects, technical solutions and advantages of the present application clearer, the following will combine the embodiments of the present application to make a clear and complete description of the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only a part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative work belong to the protection scope of the present application. If the specific technology or condition is not specified in the embodiments, the technology or condition described in the literature in the art or according to the product instruction is adopted. If the manufacturer of the reagent or instrument is not specified, it is a conventional product that can be obtained in the market.
[0041] In the following description, the term “and / or” is used to describe the association relationship of the associated objects, which means that there can be three kinds of relationships, for example, A and / or B, which can represent the cases of A alone, B alone and A and B existing at the same time. Wherein A and B can be singular or plural.
[0042] Those skilled in the art should understand that in the following description of the embodiments of the present application, the order of the serial numbers does not mean the order of execution, and part or all of the steps can be executed in parallel or in sequence, and the execution order of each process should be determined according to its function and inherent logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.
[0043] Those skilled in the art should understand that the numerical range in the embodiments of the present application should be understood as also specifically disclosing each intermediate value between the upper limit and the lower limit of the range. Each smaller range between any stated value or intermediate value in the stated range and any other stated value or intermediate value in the stated range is also included in the present application. The upper limit and the lower limit of these smaller ranges can be independently included or excluded from the range.
[0044] Unless otherwise specified, the technical / scientific terms used herein have the same meaning as generally understood by those skilled in the art to which the present application belongs. Although only preferred methods and materials are described, any methods and materials similar or equivalent to those described herein can also be used in the implementation or testing of the present application. All documents mentioned in the specification are incorporated by reference to disclose and describe the methods and / or materials related to the documents. In the event of conflict between any incorporated document and the content of the specification, the content of the specification shall prevail.
[0045] A first aspect of the present application provides a hydrogel, which is obtained by photo-crosslinking solidification of a hydrogel precursor solution comprising acrylated β-cyclodextrin, acrylated alendronate sodium, gelatin and a chemokine;
[0046] The structural formula of the acrylated β-cyclodextrin is shown as formula (1), and the structural formula of the acrylated alendronate sodium is shown as formula (2):
[0047]
[0048] The chemotactic factor is any one of SDF-1α, CCL25, VEGF and stem cell homing peptide.
[0049] In the present application, the acrylated β-cyclodextrin (Ac-β-CD) participates in the photocrosslinking curing process through acrylate groups and regulates the release of drugs (SDF-1α in the present application) and provides a growth environment for cells (BMSCs in the present application) through host-guest interaction, which refers to the non-covalent interaction between the hydrophobic cavity of Ac-β-CD and the hydrophobic amino acid side chain on the gelatin molecular chain, wherein Ac-β-CD acts as the “host” and the hydrophobic amino acid side chain in the gelatin molecule acts as the “guest” and is embedded. The acrylated alendronate sodium (Ac-ALN) provides osteogenic sites (binds Ca 2 + / Mg 2+ ) and enhances the osteogenic differentiation activity of bone marrow mesenchymal stem cells (BMSCs) and promotes the osteogenic differentiation of BMSCs. Gelatin, as one of the matrix materials of the hydrogel, provides cell adhesion function and aromatic residues to achieve host-guest inclusion. The core function of the chemotactic factor is to rapidly recruit endogenous mesenchymal stem cells (BMSCs in the present application) in situ.
[0050] The present application forms a hydrogel using a hydrogel precursor solution comprising acrylated β-cyclodextrin, acrylated alendronate sodium, gelatin and a chemotactic factor, and the hydrogel has a porous network structure, high elastic modulus, high fatigue resistance and excellent biocompatibility, and it also has the ability to recruit bone marrow mesenchymal stem cells (BMSCs) and the ability to promote the osteogenic differentiation of BMSCs. The porous titanium / hydrogel composite implant material prepared using the hydrogel can effectively promote the growth of new bone tissue and has excellent osteointegration ability, and the osteogenic repair effect and the osteointegration effect are significantly improved.
[0051] The present inventors have found through a large number of studies that when alendronate sodium is not acrylated, the elastic modulus of the formed hydrogel is reduced; when β-cyclodextrin is used (i.e. β-cyclodextrin is not acrylated), the hydrogel cannot be formed; when acrylated alendronate sodium or SDF-1α is not added, the formed hydrogel has poor osteogenic effect; when β-cyclodextrin and alendronate sodium are used (i.e. both β-cyclodextrin and alendronate sodium are not acrylated), the hydrogel cannot be formed.
[0052] The principle of preparing the hydrogel of the present application is described as follows: gelatin and acrylated β-cyclodextrin (Ac-β-CD) form a hydrogel under the joint action of physical crosslinking and chemical crosslinking, which provides a growth environment for cells; the chemotactic factor can recruit endogenous mesenchymal stem cells (endogenous MSCs) in situ and make them migrate into the interior of the hydrogel; acrylated alendronate sodium (Ac-ALN) has the ability to complex Ca 2+ / Mg 2+ ions, and can promote mineralization and improve the osteogenic differentiation activity of endogenous MSCs, thereby synergistically completing the time sequence regulation of promoting the osteogenic differentiation of BMSCs. The physical crosslinking refers to the host-guest interaction between the above-mentioned gelatin and acrylated β-cyclodextrin (Ac-β-CD); the chemical crosslinking refers to that under light irradiation, the initiator (phenyl (2, 4, 6-trimethylbenzoyl) lithium phosphate salt) generates free radicals, which attack the carbon-carbon double bond on Ac-β-CD, initiate a radical polymerization reaction, and the double bonds between multiple Ac-β-CD molecules are connected to each other to form a covalent bond, thereby constructing a stable and irreversible chemical crosslinking network.
[0053] In a specific embodiment, the mass ratio of acrylated β-cyclodextrin, acrylated alendronate sodium, gelatin and chemotactic factor in the hydrogel precursor solution is (4-6) : (1.5-2.5) : (3-5) : 25 x 10 -9 .
[0054] In a specific embodiment, the chemotactic factor is at least one of stromal cell-derived factor-1α (SDF-1α), chemokine ligand 25 (CCL25), vascular endothelial growth factor (VEGF), and stem cell homing peptide.
[0055] When the above-mentioned substance is used as a chemotactic factor, it not only can match with acrylated β-cyclodextrin, acrylated alendronate sodium, gelatin and the like to form a hydrogel with a porous network structure, but also can make the formed hydrogel recruit endogenous MSCs (BMSCs in the embodiment of the present application) in situ and rapidly.
[0056] In a specific embodiment, the photo-crosslinking curing comprises: irradiating under 5 mW / cm 2 -15 mW / cm 2 of intensity and 365 nm-405 nm violet light for 1 min-10 min for photo-crosslinking curing.
[0057] In the present application, the photocrosslinking curing can occur at room temperature without heating, which is very advantageous for protecting chemotactic factors (such as SDF-1α); while thermal curing usually requires heating to a higher temperature, which has the risk of denaturing and inactivating chemotactic factors (such as SDF-1α).
[0058] When the photocrosslinking curing is carried out under the above conditions, the reaction conditions are mild, the reaction is fast, and the cells are friendly, etc.
[0059] In a specific embodiment, the above-mentioned acrylated β-cyclodextrin is obtained by a preparation method comprising the following processes:
[0060] The β-cyclodextrin, dimethylformamide and triethylamine are mixed to prepare a β-cyclodextrin solution, acryloyl chloride is added to the β-cyclodextrin solution under ice bath conditions for stirring reaction, after the reaction is completed, insoluble substances are removed by filtration, rotary evaporation is performed, and precipitation is performed in acetone to obtain precipitate, i.e. the acrylated β-cyclodextrin.
[0061] In a specific embodiment, the above-mentioned acrylated alendronate sodium is obtained by a preparation method comprising the following processes:
[0062] Alendronate sodium, potassium carbonate, diethyl ether and sodium hydroxide are dissolved in water to prepare an alendronate sodium solution, acryloyl chloride is dissolved in anhydrous diethyl ether to prepare an acryloyl chloride diethyl ether solution, the acryloyl chloride diethyl ether solution is added to the alendronate sodium solution under ice bath conditions for stirring reaction, after the reaction is completed, acidification is performed with hydrochloric acid to pH = 1-3, extraction is performed with diethyl ether, pH is adjusted to 6.5-7.5, and precipitation is performed in ethanol to obtain precipitate, i.e. the acrylated alendronate sodium.
[0063] The second aspect of the present application provides a porous titanium / hydrogel composite implant material, comprising a porous titanium alloy material and a hydrogel perfused in the pores of the porous titanium alloy material; the hydrogel is the above-mentioned hydrogel.
[0064] Research shows that the porous titanium / hydrogel composite implant material can effectively promote the growth of new bone tissue, has excellent bone integration ability, and the osteogenesis repair effect and bone integration effect are obviously improved.
[0065] In a specific embodiment, the mass of the hydrogel accounts for 75%-85% of the total mass of the porous titanium / hydrogel composite implant material.
[0066] The third aspect of the present application provides a preparation method of the above-mentioned porous titanium / hydrogel composite implant material, comprising the following steps:
[0067] (1) The acrylated β-cyclodextrin, acrylated alendronate sodium, gelatin, chemotactic factor and solvent are thoroughly mixed to prepare a hydrogel precursor solution;
[0068] (2) perfuse the hydrogel precursor solution into the pores of the porous titanium alloy material, add a phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution, and perform photo-crosslinking and curing to obtain a porous titanium / hydrogel composite implant material.
[0069] In the present application, the phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution is prepared by dissolving phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt in a PBS buffer.
[0070] Phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt (LAP) is a high-efficiency, cell-compatible water-soluble photoinitiator. Compared with traditional photoinitiators (such as Irgacure 2959), LAP has higher initiation efficiency under 405 nm violet light and lower free radical toxicity, which can minimize the damage to biological macromolecules such as SDF-1α during photo-crosslinking and curing. Compared with certain chemical crosslinking agents (such as glutaraldehyde), the photo-crosslinking and curing process does not introduce chemical small molecule residues that may have toxic side effects on chemotactic factors.
[0071] The porous titanium / hydrogel composite implant material of the present application is obtained by perfusing a hydrogel precursor solution into the pores of a porous titanium alloy material and performing in-situ photo-crosslinking and curing. The porous titanium / hydrogel composite implant material can regulate the osteogenic differentiation activity of endogenous MSCs (BMSCs in the present application) on the basis of providing stress support, avoid mechanical imbalance caused by the mismatch between material degradation and bone regeneration rate, enhance the osteoinductive activity of hard tissue replacement scaffolds, improve the bone ingrowth rate and depth, promote osteogenic repair effect and bone integration effect, and realize the synergistic performance of mechanical stability and biological repair. In addition, the porous titanium / hydrogel composite implant material has the characteristics of simple manufacturing process, scalable production, easy quality control, long-term storage, and convenient transportation, and has great application potential in SBDs repair therapy.
[0072] In a specific embodiment, the concentration of the phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution is 5 mg / mL-15 mg / mL.
[0073] The present application will be further described below through specific examples.
[0074] In the following examples, the β-cyclodextrin was purchased from Aladdin Biochem Technology Co., Ltd. (item number C104384-500g); the sodium alendronate was purchased from Shanghai Adamas Reagent Co., Ltd. (item number 17408E); the acryloyl chloride was purchased from Beijing Bailingwei Technology Co., Ltd. (item number 948010); the SDF-1α was purchased from Shanghai Biyuntian Biotechnology Co., Ltd. (item number P6537-10μg); the bone marrow mesenchymal stem cells (BMSCs) were extracted from 3-week-old male Sprague-Dawley rats, which were purchased from Chongqing Enswell Biological Technology Co., Ltd.; the PBS buffer solution without calcium and magnesium ions was purchased from Wuhan Sivell Biological Technology Co., Ltd. (item number G4202-500ML); the porous titanium alloy material was purchased from Beijing Aikangyicheng Medical Instrument Co., Ltd.; the DMEM culture medium was purchased from Platinum Titanium Trade (Chongqing) Co., Ltd. (item number D6515-500ml), the fetal bovine serum was purchased from Platinum Titanium Trade (Chongqing) Co., Ltd. (item number F917980-500ml), and the penicillin-streptomycin was purchased from Shanghai Titan Science and Technology Co., Ltd. (C8021-100mL).
[0075] Example 1
[0076] The hydrogel provided in this example is obtained by a preparation method comprising the following processes:
[0077] (1) Preparation of acrylated β-cyclodextrin (Ac-β-CD): 6g of β-cyclodextrin (β-CD), 100mL of dimethylformamide and 4mL of triethylamine were mixed to prepare a β-cyclodextrin solution, 6.75mL of acryloyl chloride was added to the β-cyclodextrin solution under ice bath condition, and stirring reaction was performed for 12h. After the reaction was completed, the insoluble substances were removed by filtration, and the clear solution was obtained by rotary evaporation using a vacuum rotary evaporator. The clear solution was precipitated in 200mL of acetone to obtain a precipitate, which was washed with acetone and vacuum dried to obtain acrylated β-cyclodextrin (Ac-β-CD);
[0078] (2) Preparation of acrylated sodium alendronate (Ac-ALN): 6g of sodium alendronate (ALN), 6g of potassium carbonate, 15mL of diethyl ether and 0.4g of sodium hydroxide were dissolved in 25mL of water to prepare a sodium alendronate solution;
[0079] 2.5mL of acryloyl chloride was dissolved in 10mL of anhydrous diethyl ether to prepare an acryloyl chloride diethyl ether solution;
[0080] The acrylated alendronate sodium (Ac-ALN) was prepared by adding acryloyl chloride in ethyl ether solution to the alendronate sodium solution under ice bath condition and stirring for 12 h. After the reaction was completed, the reaction solution was acidified to pH = 2 with 1 mol / L hydrochloric acid solution, extracted with ethyl ether, adjusted to pH = 7 with 1 mol / L sodium hydroxide solution, precipitated in ethanol to obtain a precipitate, and freeze-dried at -80°C for 72 h.
[0081] (3) Preparation of the hydrogel precursor solution: SDF-1α was dissolved in PBS buffer to prepare a SDF-1α solution with a concentration of 500 ng / mL (i.e., 500 ng / mL SDF-1α solution); phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt was dissolved in PBS buffer to prepare a phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution with a concentration of 10 mg / mL (i.e., 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution);
[0082] 0.5 g of acrylated β-cyclodextrin (Ac-β-CD), 0.2 g of acrylated alendronate sodium (Ac-ALN), and 0.4 g of gelatin were fully dissolved in 4 mL of calcium and magnesium ion-free PBS buffer, 0.5 mL of 500 ng / mL SDF-1α solution and 0.5 mL of 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution were added, and the mixture was fully vortexed at 37°C to prepare a hydrogel precursor solution;
[0083] (4) Preparation of the hydrogel: the hydrogel precursor solution was irradiated under 405 nm violet light with an intensity of 10 mW / cm 2 for 5 min for photo-crosslinking and curing to obtain a hydrogel.
[0084] Comparative Example 1 (β-cyclodextrin without acrylation)
[0085] The hydrogel provided by the present comparative example was prepared by a preparation method comprising the following processes:
[0086] (1) Preparation of acrylated alendronate sodium (Ac-ALN): consistent with the preparation of acrylated alendronate sodium (Ac-ALN) in Example 1;
[0087] (2) Preparation of the hydrogel precursor solution: SDF-1a was dissolved in PBS buffer to prepare a SDF-1a solution with a concentration of 500 ng / mL (i.e., 500 ng / mL SDF-1a solution); phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt was dissolved in PBS buffer to prepare a phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution with a concentration of 10 mg / mL (i.e., 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution);
[0088] 0.5 g of β-cyclodextrin (β-CD), 0.2 g of acrylated alendronate sodium (Ac-ALN), and 0.4 g of gelatin were fully dissolved in 4 mL of PBS buffer without calcium and magnesium ions, 0.5 mL of 500 ng / mL SDF-1a solution and 0.5 mL of 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution were added, and the mixture was fully vortexed at 37°C to prepare a hydrogel precursor solution.
[0089] The hydrogel precursor solution in the present comparative example was irradiated with a 405 nm violet light with an intensity of 10 mW / cm 2 for 5 min for photo-crosslinking solidification, and the inventors found that the hydrogel precursor solution in the present comparative example could not be gelled, i.e., could not form a hydrogel, and no subsequent performance test was performed.
[0090] Comparative Example 2 (alendronate sodium without acrylation)
[0091] The hydrogel provided by the present comparative example was obtained by a preparation method comprising the following processes:
[0092] (1) Preparation of acrylated β-cyclodextrin (Ac-β-CD): consistent with the preparation of acrylated β-cyclodextrin (Ac-β-CD) in Example 1;
[0093] (2) Preparation of the hydrogel precursor solution: SDF-1a was dissolved in PBS buffer to prepare a SDF-1a solution with a concentration of 500 ng / mL (i.e., 500 ng / mL SDF-1a solution); phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt was dissolved in PBS buffer to prepare a phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution with a concentration of 10 mg / mL (i.e., 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution);
[0094] A hydrogel precursor solution was prepared by dissolving 0.5 g of acrylated β-cyclodextrin (Ac-β-CD), 0.2 g of alendronate sodium (ALN) and 0.4 g of gelatin in 4 mL of calcium-magnesium ion-free PBS buffer, adding 0.5 mL of a 500 ng / mL SDF-1α solution and 0.5 mL of a 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate solution, and thoroughly vortexing at 37°C.
[0095] (3) Preparation of the hydrogel: The hydrogel precursor solution was irradiated under 405 nm violet light at an intensity of 10 mW / cm 2 for 5 min for photo-crosslinking and curing to obtain the hydrogel.
[0096] Comparative Example 3 (neither the β-cyclodextrin nor the alendronate sodium was acrylated)
[0097] The hydrogel provided by the present comparative example was obtained by a preparation method comprising the following processes:
[0098] (1) Preparation of the hydrogel precursor solution: SDF-1α was dissolved in a PBS buffer to obtain a SDF-1α solution with a concentration of 500 ng / mL (i.e., a 500 ng / mL SDF-1α solution); phenyl (2,4,6-trimethylbenzoyl) lithium phosphate was dissolved in a PBS buffer to obtain a phenyl (2,4,6-trimethylbenzoyl) lithium phosphate solution with a concentration of 10 mg / mL (i.e., a 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate solution);
[0099] A hydrogel precursor solution was prepared by dissolving 0.5 g of β-cyclodextrin (β-CD), 0.2 g of alendronate sodium (ALN) and 0.4 g of gelatin in 4 mL of calcium-magnesium ion-free PBS buffer, adding 0.5 mL of a 500 ng / mL SDF-1α solution and 0.5 mL of a 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate solution.
[0100] The hydrogel precursor solution in the present comparative example was irradiated under 405 nm violet light at an intensity of 10 mW / cm 2 for 5 min for photo-crosslinking and curing, and the inventors found that the hydrogel precursor solution in the present comparative example could not be gelled, i.e., could not form a hydrogel, and thus no subsequent performance test was performed.
[0101] Comparative Example 4 (no acrylated alendronate sodium was added)
[0102] The hydrogel provided by the present comparative example was obtained by a preparation method comprising the following processes:
[0103] (1) Preparation of acrylated β-cyclodextrin (Ac-β-CD): consistent with the preparation of acrylated β-cyclodextrin (Ac-β-CD) in Example 1;
[0104] (2) Preparation of hydrogel precursor solution: SDF-1α was dissolved in PBS buffer to obtain a SDF-1α solution with a concentration of 500 ng / mL (i.e. 500 ng / mL SDF-1α solution); phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt was dissolved in PBS buffer to obtain a phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution with a concentration of 10 mg / mL (i.e. 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution);
[0105] 0.5 g of acrylated β-cyclodextrin (Ac-β-CD) and 0.4 g of gelatin were fully dissolved in 4 mL of PBS buffer without calcium and magnesium ions, 0.5 mL of 500 ng / mL SDF-1α solution was added, 0.5 mL of 500 ng / mL SDF-1α solution and 0.5 mL of 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution were added, and the mixture was fully vortexed at 37°C to obtain a hydrogel precursor solution.
[0106] (3) Preparation of hydrogel: the hydrogel precursor solution was irradiated for 5 min under 405 nm violet light with an intensity of 10 mW / cm 2 to perform photo-crosslinking solidification, thereby obtaining a hydrogel.
[0107] Comparative Example 5 (without SDF-1α)
[0108] The preparation of the hydrogel provided in this comparative example is basically consistent with that in Example 1, except that:
[0109] (3) Preparation of hydrogel precursor solution: 0.5 g of acrylated β-cyclodextrin (Ac-β-CD), 0.2 g of acrylated alendronate sodium (Ac-ALN) and 0.4 g of gelatin were fully dissolved in 4 mL of PBS buffer without calcium and magnesium ions, 0.5 mL of 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution was added, and the mixture was fully vortexed at 37°C to obtain a hydrogel precursor solution.
[0110] Example 2
[0111] The porous titanium / hydrogel composite implant material provided in this example is obtained by a preparation method comprising the following processes:
[0112] (1) Preparation of 3D-printed porous titanium alloy: a 3D-printed porous titanium alloy material is prepared into a cylinder with a diameter of 1 cm and a length of 1.5 cm by using a 3D printing technology, and the 3D-printed porous titanium alloy is obtained, wherein the average pore size of the 3D-printed porous titanium alloy is 500 μm, and the average porosity is 80%;
[0113] (2) A phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution with a concentration of 10 mg / mL is prepared by dissolving the phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt in a PBS buffer solution (i.e., a 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution);
[0114] (3) 5 mL of the hydrogel precursor solution prepared in Example 1 is perfused into the pores of 1.5 g of the 3D-printed porous titanium alloy by using a pressurized perfusion system, 0.5 mL of the 10 mg / mL phenyl (2,4,6-trimethylbenzoyl) lithium phosphate salt solution is added, and the solution is irradiated under a 405 nm violet light with an intensity of 10 mW / cm 2 for 5 min for photo-crosslinking and curing, so that the hydrogel precursor solution perfused in the pores of the porous titanium alloy material forms a hydrogel, and finally a porous titanium / hydrogel composite implant material is obtained; in the porous titanium / hydrogel composite implant material, the mass of the hydrogel accounts for 80.5% of the total mass of the porous titanium / hydrogel composite implant material.
[0115] Example 3
[0116] This example provides a 3D-printed porous titanium alloy without any treatment (the same as the preparation of the 3D-printed porous titanium alloy in Example 2).
[0117] Performance test
[0118] 1. The nuclear magnetic hydrogen spectrum test is performed on the β-cyclodextrin (β-CD), acrylated β-cyclodextrin (Ac-β-CD), sodium alendronate (ALN), and acrylated sodium alendronate (Ac-ALN) in Example 1 of the present application, and the results are shown in FIGS. Figure 1 and Figure 2 Figure 1 FIG. 1 is the nuclear magnetic hydrogen spectrum of the β-cyclodextrin (β-CD) and acrylated β-cyclodextrin (Ac-β-CD) in Example 1 of the present application; Figure 2 FIG. 2 is the nuclear magnetic hydrogen spectrum of the sodium alendronate (ALN) and acrylated sodium alendronate (Ac-ALN) in Example 1 of the present application.
[0119] Figure 1 As can be seen, compared with β-CD, the characteristic signal peak of the 1H NMR spectrum appeared at 6.25 ppm, indicating that the acryloyl group with carbon-carbon double bond has been successfully grafted onto β-CD through ester bond, that is, the acrylic β-cyclodextrin (Ac-β-CD) was successfully prepared. The chemical structure of Ac-β-CD is as follows:
[0120]
[0121] Depend on Figure 2 As can be seen, compared with ALN, the characteristic signal peak of acryloyl group appeared in the 1H NMR spectrum at 5.8-6.4 ppm, indicating that the acryloyl group with carbon-carbon double bond has been successfully grafted onto ALN through ester bond, that is, the acrylated sodium alendronate (Ac-ALN) was successfully prepared. The chemical structure of Ac-ALN is as follows:
[0122]
[0123] 2. The hydrogel in Example 1 of this invention was subjected to scanning electron microscopy and X-ray energy dispersive spectroscopy tests, such as... Figure 3 and Figure 4 As shown; Figure 3 This is a scanning electron microscope image of the hydrogel in Example 1 of the present invention; Figure 4 The X-ray energy dispersive spectroscopy (EDS) results are shown for the hydrogel in Example 1 of this invention.
[0124] Depend on Figure 3 and Figure 4 It is known that the hydrogel provided by the present invention has a porous network structure and contains C, N, O and P elements.
[0125] 3. The mechanical properties of the hydrogels in Example 1 and Comparative Example 2 of the present invention were tested respectively, and the results are as follows: Figures 5-6 As shown.
[0126] Figure 5 The mechanical property test results of the hydrogel in Example 1 of this invention are shown below. Figure 5 'a' represents the uniaxial compressive stress / strain curve of the hydrogel. Figure 5 b represents the stress relaxation curve of the hydrogel. Figure 5 c represents the cyclic compressive stress / strain curve of the hydrogel. Figure 5 d represents the rheological curve of the hydrogel. (From...) Figure 5 As can be seen from a, the hydrogel in Example 1 has a high elastic modulus (4.43 kPa), indicating that the hydrogel in Example 1 can provide good mechanical support. Figure 5 As can be seen from b, the hydrogel in Example 1 can gradually disperse stress through molecular chain rearrangement, avoiding continuous pressure on surrounding tissues, demonstrating good energy dissipation capability. Figure 5It can be known from c that the multiple cycle curves are highly overlapped and the hysteresis loop is small, indicating that the hydrogel in Example 1 has excellent elastic recovery ability and fatigue resistance, and can withstand repeated loads for a long time without permanent deformation or damage. Figure 5 It can be known from d that the storage modulus of the hydrogel in Example 1 is always higher than the loss modulus, and remains stable at different frequencies, proving that the hydrogel in Example 1 has a stable gel network structure and excellent mechanical stability.
[0127] Figure 6 a is the uniaxial compression stress / strain curve of the hydrogel in Comparative Example 2, Figure 6 b is the uniaxial compression stress / strain curve of the hydrogel in Example 1. It can be known from c that the multiple cycle curves are highly overlapped and the hysteresis loop is small, indicating that the hydrogel in Example 1 has excellent elastic recovery ability and fatigue resistance, and can withstand repeated loads for a long time without permanent deformation or damage. It can be known from d that the storage modulus of the hydrogel in Example 1 is always higher than the loss modulus, and remains stable at different frequencies, proving that the hydrogel in Example 1 has a stable gel network structure and excellent mechanical stability. Figure 6 Figure 6 It can be known from c that the multiple cycle curves are highly overlapped and the hysteresis loop is small, indicating that the hydrogel in Example 1 has excellent elastic recovery ability and fatigue resistance, and can withstand repeated loads for a long time without permanent deformation or damage. It can be known from d that the storage modulus of the hydrogel in Example 1 is always higher than the loss modulus, and remains stable at different frequencies, proving that the hydrogel in Example 1 has a stable gel network structure and excellent mechanical stability.
[0128] 4. The hydrogel in Example 1 of the present application was tested for biocompatibility, and the specific method included:
[0129] The bone marrow mesenchymal stem cells (BMSCs) were digested and centrifuged to obtain cell precipitate, resuspended and uniformly blown with the hydrogel precursor solution (prepared according to the process of preparing the hydrogel precursor solution in Example 1), and irradiated under 10 mW / cm 2 , wavelength 405 nm violet light for 5 min to form a hydrogel, which was cultured in a culture medium (DMEM culture medium + 10% fetal bovine serum + 1% penicillin-streptomycin) for 3 days, and then the activity of BMSCs in the hydrogel was observed by using Calcein / PI cell activity / toxicity detection reagent, and the results are shown in Figure 7 . Figure 7 The biocompatibility test results of the hydrogel in Example 1 of the present application are shown in Table 2.
[0130] It can be known from c that the multiple cycle curves are highly overlapped and the hysteresis loop is small, indicating that the hydrogel in Example 1 has excellent elastic recovery ability and fatigue resistance, and can withstand repeated loads for a long time without permanent deformation or damage. It can be known from d that the storage modulus of the hydrogel in Example 1 is always higher than the loss modulus, and remains stable at different frequencies, proving that the hydrogel in Example 1 has a stable gel network structure and excellent mechanical stability. Figure 7 It can be known from c that the multiple cycle curves are highly overlapped and the hysteresis loop is small, indicating that the hydrogel in Example 1 has excellent elastic recovery ability and fatigue resistance, and can withstand repeated loads for a long time without permanent deformation or damage. It can be known from d that the storage modulus of the hydrogel in Example 1 is always higher than the loss modulus, and remains stable at different frequencies, proving that the hydrogel in Example 1 has a stable gel network structure and excellent mechanical stability.
[0131] 5. The hydrogel in Example 1 of the present application was tested for cell recruitment ability, and the specific method included:
[0132] A 48-well plate was used as a mold to prepare hydrogels within the wells (prepared according to the hydrogel preparation process in Example 1). BMSCs were labeled with DiO (purchased from Shanghai Beyotime Biotechnology Co., Ltd., catalog number C1993S) and then seeded onto the hydrogel surface. The hydrogel was vertically cut in half at 6 h and 30 h, and the depth of BMSC growth within the hydrogel was observed using confocal fluorescence microscopy. The results are as follows: Figure 8 As shown. Figure 8 The results of the cell recruitment ability test of the hydrogel in Example 1 of this invention are shown below. Figure 8 Image a is a confocal fluorescence microscope image of BMSCs seeded on the hydrogel surface 6 hours after implantation, and image b is a confocal microscope image of BMSCs seeded on the hydrogel surface 30 hours after implantation.
[0133] Depend on Figure 8 It can be seen that BMSCs on the surface of the hydrogel can migrate and grow into the interior as the culture time increases, indicating that the hydrogel provided by the present invention has cell recruitment ability.
[0134] 6. Test of osteogenic differentiation capacity of cells
[0135] (1) The hydrogel precursor solution from Example 1 was spin-coated onto the surface of a titanium foil (0.25 mm thick, 1 cm x 1 cm in area) at a strength of 10 mW / cm. 2 Hydrogels were formed by irradiation under 405nm ultraviolet light for 5 min. BMSCs were then inoculated onto the surface of the hydrogel and cultured in DMEM medium (10% fetal bovine serum + 1% penicillin-streptomycin) as the hydrogel experimental group. BMSCs were also inoculated onto titanium foil (0.25mm thick, 1cm x 1cm) and cultured in DMEM medium (10% fetal bovine serum + 1% penicillin-streptomycin) as the control group. Staining was performed using an alkaline phosphatase assay kit on Day 4 and Day 7, and the results were observed and photographed under a stereomicroscope. The results are shown below. Figure 9 As shown. Figure 9 The staining results of the hydrogel experimental group and the control group in the osteogenic differentiation ability test (1) of the present invention are shown.
[0136] Depend on Figure 9 It can be seen that, compared with the control group, the hydrogel experimental group had higher alkaline phosphatase content on days 4 and 7, indicating that the hydrogel provided by the present invention can effectively promote osteogenic differentiation of BMSCs and has excellent ability to promote osteogenic differentiation of cells.
[0137] (2) The hydrogel precursor solutions (Gel+Ac-Aln+SDF1α) from Example 1, (Ti+Gel+SDF-1α) from Comparative Example 4, and (Ti+Gel+Ac-Aln) from Comparative Example 5 were spin-coated onto the surface of titanium foil (0.25 mm thick, 1 cm * 1 cm in area). The solutions were then irradiated for 5 min under 10 mW / cm² violet light at a wavelength of 405 nm to form hydrogels. BMSCs were inoculated onto the hydrogel surface and cultured in a culture medium (DMEM medium + 10% fetal bovine serum + 1% penicillin-streptomycin). These solutions were used as Ti+Gel+Ac-Aln+SDF1α solutions, respectively. The study included three groups: F1α, Ti+Gel+SDF-1α, and Ti+Gel+Ac-Aln. Simultaneously, BMSCs were seeded onto titanium foil (0.25 mm thick, 1 cm x 1 cm in area) and cultured in DMEM medium (10% fetal bovine serum + 1% penicillin-streptomycin) as a control group. Cell lysis was performed at 4°C for 30 min on days 4 and 7, respectively. Cell lysates were collected, and the total protein content and ALP content were measured using an enhanced BCA protein assay kit and an alkaline phosphatase (AKP / ALP) test kit. The alkaline phosphatase activity per gram of protein was calculated (ALP content divided by total protein content). Results are shown below. Figure 10 As shown. Figure 10 The alkaline phosphatase activity test results of the control group (Ti), Ti+Gel+Ac-Aln+SDF1α group (Ti+Gel+Ac-Aln+SDF1α), Ti+Gel+SDF-1α group (Ti+Gel+SDF-1α) and Ti+Gel+Ac-Aln group (Ti+Gel+Ac-Aln) in the osteogenic differentiation ability test (2) of the present invention are as follows.
[0138] Depend on Figure 10 It can be seen that, compared with the control group (Ti), the Ti+Gel+Ac-Aln+SDF1α group, the Ti+Gel+SDF-1α group, and the Ti+Gel+Ac-Aln group all had higher alkaline phosphatase content. The alkaline phosphatase content of the Ti+Gel+SDF-1α group and the Ti+Gel+Ac-Aln group was significantly lower than that of the Ti+Gel+Ac-Aln+SDF1α group, indicating that the hydrogel formed without the addition of Ac-Aln and SDF-1α had a poor osteogenic effect.
[0139] 7. Performance testing of porous titanium / hydrogel composite implant materials
[0140] Laboratory animals: New Zealand white rabbits, male, purchased from Chongqing Watson Biotechnology Co., Ltd.
[0141] Construction of segmental bone defect model:
[0142] 1) Prepare a pentobarbital sodium solution with a concentration of 0.02 g / mL by mixing pentobarbital sodium with pure water;
[0143] 2) Anesthetize the New Zealand white rabbits by injecting the marginal ear vein and place them on a sterile clean operating table;
[0144] 3) After disinfecting the shaved legs of the New Zealand white rabbits with iodophor, make a longitudinal skin incision on the lateral thigh with a sterile scalpel, about 6 cm in length, and cut open the skin and subcutaneous fascia layer by layer; bluntly separate the lateral femoral muscle group, enter along the intermuscular space, and avoid excessive muscle damage; carefully peel off the periosteum of the middle femoral shaft using a periosteal elevator, fully expose the surgical field, and place the selected bone plate on the anterior-lateral surface of the femur; use a drill guide to pre-drill the hole at the planned screw hole site, and then implant all the screws; mark the segment to be removed (1.5 cm) on the femur below the middle of the bone plate with a marker pen; use a bone saw to cut perpendicular to the long axis of the femur on both sides of the marked line, and use tissue forceps to remove the cut bone segment; finally tighten the bone plate screws one by one to ensure that the bone plate stably fixes the bone segments at both ends of the defect;
[0145] Randomly divide into 3 groups (3 rabbits per group):
[0146] Control group (Control): No implantation of any material, the surgical wound is thoroughly flushed with sterile normal saline, all bone debris and blood clots are removed, absorbable sutures are used to suture the muscle fascia layer and skin wound layer by layer, and finally the wound surface is disinfected again with iodophor;
[0147] Control group (Ti): The 3D printed porous titanium alloy (i.e. titanium implant) in Example 3 is precisely implanted into the defect gap, ensuring good contact between the material and the bone ends, the surgical wound is thoroughly flushed with sterile normal saline, all bone debris and blood clots are removed, absorbable sutures are used to suture the muscle fascia layer and skin wound layer by layer, and finally the wound surface is disinfected again with iodophor;
[0148] Experimental group (Ti+Gel): The porous titanium / hydrogel composite implant material (i.e. titanium implant) in Example 2 is precisely implanted into the defect gap, ensuring good contact between the material and the bone ends, the surgical wound is thoroughly flushed with sterile normal saline, all bone debris and blood clots are removed, absorbable sutures are used to suture the muscle fascia layer and skin wound layer by layer, and finally the wound surface is disinfected again with iodophor;
[0149] 12 weeks later, the New Zealand white rabbits in each group were anesthetized and euthanized, a skin incision was made around the original surgical incision scar, and the femoral region was fully exposed; the skin and subcutaneous tissue were carefully stripped; using a scalpel, tissue scissors and periosteum stripper, the muscle, fascia and connective tissue wrapped around the femur and bone plate were carefully removed; using a screwdriver matched with the bone plate screw, all the screws were screwed out one by one and the bone plate was carefully removed; after separating the hip joint and the knee joint, the soft tissue connection was completely disconnected, and the "femur-titanium implant-femur" complex was completely removed, and then Micro-CT was used for scanning and Ctan software was used for analyzing the scanning results, as shown in Figure 11 and Figure 12 . Figure 11 The performance test of the porous titanium / hydrogel composite implant material of the application, wherein Figure 11 a is the femur of the New Zealand white rabbit, Figure 11 b and c are real images of the 3D printed porous titanium alloy, Figure 11 d is a pressurized perfusion system designed with a 5ml syringe, Figure 11 e is an image of the hydrogel formed by the hydrogel precursor solution perfused in the pores of the porous titanium alloy material; Figure 12 The performance test results of the porous titanium / hydrogel composite implant material of the application, Figure 12 a is the bone volume fraction calculated after Micro-CT detection of each group, Figure 12 b is the trabecular bone thickness of each group, Figure 12 c is the trabecular bone number of each group, Figure 12 d is the trabecular bone spacing of each group.
[0150] As can be seen from Figure 11 and Figure 12 , compared with the blank group and the control group, the bone volume fraction of the experimental group is significantly improved, the trabecular bone thickness and the trabecular bone number are significantly improved, and the trabecular bone spacing is significantly reduced, indicating that the porous titanium / hydrogel composite implant material provided by the application can effectively promote the growth of new bone tissue and has excellent bone integration ability.
[0151] Finally, it should be noted that: the above examples are only used to illustrate the technical solutions of the application, and not to limit them; although the application has been described in detail with reference to the foregoing examples, those skilled in the art should understand that they can still modify the technical solutions described in the foregoing examples, or make equivalent substitutions for part or all of the technical features; and these modifications or substitutions do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the application.
Claims
1. A hydrogel, characterized in that, The hydrogel is obtained by photo-crosslinking solidification of a hydrogel precursor solution comprising acrylated β-cyclodextrin, acrylated alendronate sodium, gelatin and a chemotactic factor; The acrylated β-cyclodextrin has a structural formula as shown in formula (1), and the acrylated alendronate sodium has a structural formula as shown in formula (2): The chemotactic factor is any one of SDF-1α, CCL25, VEGF and stem cell homing peptide.
2. The hydrogel of claim 1, wherein, The mass ratio of acrylated β-cyclodextrin, acrylated alendronate sodium, gelatin and chemokine in the hydrogel precursor solution is (4-6):(1.5-2.5):(3-5):25x10 -9 .
3. The hydrogel according to claim 1 or 2, characterized in that, The chemotactic factor is at least one of SDF-1α, CCL25, VEGF and stem cell homing peptide.
4. The hydrogel of claim 1, wherein, The photo-crosslinking curing includes: irradiating under 5 mW / cm 2 -15 mW / cm 2 of intensity, 365 nm-405 nm violet light of wavelength for 1 min-10 min for photo-crosslinking curing.
5. The hydrogel of claim 1, wherein, The acrylated β-cyclodextrin is obtained by a preparation method comprising the following steps: The β-cyclodextrin solution is prepared by mixing β-cyclodextrin, dimethylformamide and triethylamine, acryloyl chloride is added to the β-cyclodextrin solution under ice bath condition for stirring reaction, after the reaction is completed, insoluble substances are removed by filtration, rotary evaporation is performed, precipitation is performed in acetone, washing and drying are performed, and the acrylated β-cyclodextrin is obtained.
6. The hydrogel of claim 1, wherein, The acrylated alendronate sodium is obtained by a preparation method comprising the following steps: The acrylated alendronate sodium solution is prepared by dissolving alendronate sodium, potassium carbonate, ether and sodium hydroxide in water, the acryloyl chloride ether solution is prepared by dissolving acryloyl chloride in anhydrous ether, the acryloyl chloride ether solution is added to the alendronate sodium solution under ice bath condition for stirring reaction, after the reaction is completed, the solution is acidified to pH=1-3 with hydrochloric acid, extraction is performed with ether, the pH is adjusted to 6.5-7.5, precipitation is performed in ethanol, and freeze-drying is performed, and the acrylated alendronate sodium is obtained.
7. A porous titanium / hydrogel composite implant material, characterized by, The porous titanium alloy material and the hydrogel filled in the pores of the porous titanium alloy material; The hydrogel is the hydrogel according to any one of claims 1-6.
8. The porous titanium / hydrogel composite implant material of claim 7, wherein, The mass of the hydrogel accounts for 75%-85% of the total mass of the porous titanium / hydrogel composite implant material.
9. A method for preparing the porous titanium / hydrogel composite implant material according to claim 7 or 8, characterized by, The method comprises the following steps: (1) The acrylated β-cyclodextrin, acrylated alendronate sodium, gelatin, chemotactic factor and solvent are fully mixed to prepare a hydrogel precursor solution; (2) The hydrogel precursor solution is filled into the pores of the porous titanium alloy material, a phenyl(2,4,6-trimethylbenzoyl) lithium phosphate solution is added, photo-crosslinking solidification is performed, and a porous titanium / hydrogel composite implant material is obtained.
10. The method for preparing the porous titanium / hydrogel composite implant material according to claim 9, characterized in that, The concentration of the phenyl(2,4,6-trimethylbenzoyl) lithium phosphate solution is 5 mg / mL-15 mg / mL.
